How an AI–Physics Hybrid Generalized to Unseen Antibodies—Without Benchmark-Specific Training Cross-validation can show how well a developability model performs on familiar data. But in real drug discovery, the molecules being evaluated are usually new. The real challenge is whether a model can remain reliable when it encounters molecules it has never seen before. We tested this by evaluating Apotek Landscape zero-shot on GDPa3, the blinded test panel from the 2025 Ginkgo AbD

A modular, evidence-grounded framework for rescuing, re-engineering, and accelerating biopharma assets Key Takeaways Blind Spots of Brute Force: Asset redevelopment significantly compresses clinical timelines but capturing this economic premium requires integrating heterogeneous biological, chemical, and clinical evidence into decision-ready evidence packages that conventional empirical screening cannot efficiently produce at scale. TechBio Differentiation: While generic AI

Synthesizing Fragmented Biological Signals and Biomedical Knowledge for Truth-Seeking Target Prioritization Key Takeaway Data Synthesis Bottleneck: The challenge in modern drug discovery is not a lack of data, but a lack of decision-ready synthesis. Teams need a repeatable framework to convert raw omics signals and literature hits into a prioritized, actionable discovery strategy. The Prioritization Hurdle: Teams may already have omics data, public-database hits and litera